

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of the claims:

1-56. (canceled)

57. (Currently amended) An isolated or purified ApotA-I agonist comprising the peptide Peptide PVLDFRELLNELLEALKQKLK (SEQ ID NO: 4).

58. (previously presented) A peptide-lipid complex comprising the peptide of claim 57.

59. (previously presented) The peptide-lipid complex of claim 58 wherein the lipid is a saturated lipid or unsaturated lipid or combination thereof.

60. (previously presented) The peptide-lipid complex of claim 58 wherein the lipid is a natural lipid or a synthetic lipid or combination thereof.

61. (previously presented) The peptide-lipid complex of claim 58 wherein the lipid is selected from the group consisting of small alkyl chain phospholipids, egg phosphatidylcholine, soybean phosphatidylcholine, dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine 1-myristoyl-2-palmitoylphosphatidylcholine, 1-palmitoyl-2-myristoylphosphatidylcholine, 1-palmitoyl-2-stearoylphosphatidylcholine, 1-stearoyl-2-palmitoylphosphatidylcholine, dioleoylphosphatidylcholine dioleophosphatidylethanolamine, dilauroylphosphatidylglycerol phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, sphingomyelin, sphingolipids, phosphatidylglycerol, diphosphatidylglycerol, dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol,

dioleoylphosphatidylglycerol, dimyristoylphosphatidic acid, dipalmitoylphosphatidic acid, dimyristoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, dimyristoylphosphatidylserine, dipalmitoylphosphatidylserine, brain phosphatidylserine, brain sphingomyelin, dipalmitoylsphingomyelin, distearoylsphingomyelin, phosphatidic acid, galactocerebroside, gangliosides, cerebroside, dilaurylphosphatidylcholine, (1,3)-D-mannosyl-(1,3)diglyceride, aminophenylglycoside, 3-cholesteryl-6'-(glycosylthio)hexyl ether glycolipids, and cholesterol and its derivatives.

62. (previously presented) The peptide-lipid complex of claim 58 wherein the lipid is sphingomyelin.

63. (previously presented) A pharmaceutical composition comprising the peptide according to claim 57.

64. (previously presented) The pharmaceutical composition of claim 63 that is sterile.

65. (previously presented) The pharmaceutical composition of claim 63 that is a lyophilized powder.

66. (previously presented) The pharmaceutical composition of claim 63 that is a solution.

67. (previously presented) A pharmaceutical composition comprising the peptide-lipid complex according to claims 58, 59, 60, 61 or 62.

68. (previously presented) The pharmaceutical composition of claim 67 that is sterile.

69. (previously presented) The pharmaceutical composition of claim 67 that is a lyophilized powder.

70. (previously presented) The pharmaceutical composition of claim 67 that is a

solution.

71. (previously presented) A method of treating hypercholesterolemia in a subject in need thereof, said method comprising administering to the subject an effective amount of a peptide according to claim 57.

72. (previously presented) A method of treating cardiovascular disease in a subject in need thereof, said method comprising administering to the subject an effective amount of a peptide according to claim 57.

73. (previously presented) A method of treating atherosclerosis in a subject in need thereof, said method comprising administering to the subject an effective amount of a peptide according to claim 57.

74. (previously presented) A method of treating restenosis in a subject in need thereof, said method comprising administering to the subject an effective amount of a peptide according to claim 57.

75. (previously presented) A method of treating HDL or ApoA-I deficiency in a subject in need thereof, said method comprising administering to the subject an effective amount of a peptide according to claim 57.

76. (previously presented) A method of treating hypertriglyceridemia in a subject in need thereof, said method comprising administering to the subject an effective amount of a peptide according to claim 57.

77. (previously presented) A method of treating metabolic syndrome in a subject in need thereof, said method comprising administering to the subject an effective amount of a peptide according to claim 57.

78. (previously presented) A method of treating septic shock in a subject in need thereof, said method comprising administering to the subject an effective amount of a

peptide according to claim 57.

79. (Currently amended) The method of claims 71, 72, 73, 74, 75, 76, 77 or ~~88~~ 78 wherein about 0.5 mg/kg to about 100 mg/kg of SEQ ID NO 4 is administered to said subject.